Royalty Pharma PLC

Royalty Pharma plc shareholders voted on 10 proposals at the 2026 Annual General Meeting, including director elections and compensation approvals.

Royalty Pharma plc has entered into a new $1.8 billion unsecured revolving credit agreement, refinancing its existing 2021 facility.

Royalty Pharma plc announced robust first-quarter 2026 financial results, with double-digit growth in Royalty and Portfolio Receipts, and raised its full-year 2026 guidance.

Royalty Pharma plc announced an additional $250 million funding to Revolution Medicines following positive Phase 3 trial results for daraxonrasib in pancreatic cancer.

Royalty Pharma announced robust financial results for Q4 and full year 2025, driven by double-digit portfolio growth and strategic capital deployment, alongside optimistic 2026 guidance.

Royalty Pharma plc announced the planned transition of its Executive Vice President and Chief Legal Officer, George W. Lloyd, effective December 31, 2025.

Royalty Pharma plc reported a significant increase in total income and other revenues for the first quarter of 2026, driven by strong performance across its financial royalty assets.

Royalty Pharma reports a decline in GAAP net income and EPS for Q3 and the first nine months of 2025, primarily due to accounting changes from its internalization and increased R&D funding, while Portfolio Receipts show strong growth.

Royalty Pharma plc reported a significant increase in net income and earnings per share for the first half of 2025, driven by a positive swing in non-cash provision income and robust portfolio receipts, alongside substantial share repurchases.

Royalty Pharma plc reports relatively flat income from financial royalty assets and announces progress on its internalization plans in its Q1 2025 report.

Royalty Pharma's Q3 2024 results show a significant increase in net income, reaching $806 million, driven by strong royalty income and strategic financial activities.

Royalty Pharma's second-quarter results show a slight increase in income from financial royalty assets but a decrease in other royalty income and revenues, alongside significant changes in operating expenses.

Royalty Pharma reports robust 16.2% growth in Portfolio Receipts to $3.3 billion in 2025, driven by strategic acquisitions and product performance, despite a dip in net income attributable to shareholders.

Royalty Pharma's 10-K filing reveals strong portfolio performance and a strategic move to acquire its manager, signaling a shift towards internal management.

Royalty Pharma's recent SEC filing outlines the company's share capital structure, including Class A and Class B ordinary shares, and their respective voting and dividend rights.

Royalty Pharma plc executive Marshall Urist reported the sale of 9,099 Class A Ordinary Shares under a pre-arranged 10b5-1 trading plan.

Royalty Pharma plc director Bonnie L. Bassler received Class A Ordinary Shares valued at $54,399.98 as part of her director compensation.

Royalty Pharma EVP Marshall Urist reported a sale of 9,098 Class A Ordinary Shares for approximately $55.18 per share, executed under a pre-arranged 10b5-1 trading plan.

Royalty Pharma plc reports a significant sale of Class A Ordinary Shares by EVP & Chairman, Partnering, Christopher Hite, executed under a pre-arranged trading plan.

Royalty Pharma plc director Elizabeth H. Weatherman was granted restricted stock units under the company's equity incentive plan.

Royalty Pharma Director Gregory Norden acquired 4,545 Class A Ordinary Shares through an award of restricted stock units.

Royalty Pharma plc has announced its 2026 Annual General Meeting of Shareholders will be held on June 4, 2026, and detailed strong financial and strategic execution in 2025, including significant capital deployment and shareholder returns.

Royalty Pharma plc amends its Membership Interests Purchase Agreement to include a share subscription, allowing sellers to receive Class B ordinary shares in the company.

Royalty Pharma plans to acquire its external manager, RP Management, LLC, for $200 million in cash and 24,530,266 non-voting shares, aiming to streamline operations and enhance shareholder value.

Royalty Pharma appoints Vlad Coric, CEO of Biohaven, to its Board of Directors, effective immediately.

Royalty Pharma executives discussed the recent internalization of its manager, the company's growth prospects, and its pipeline of royalty assets at the TD Cowen Healthcare Conference.

Royalty Pharma reports positive investor feedback following the J.P. Morgan Conference, highlighting excitement around the internalization of RP Management and the company's capital allocation strategy.

Royalty Pharma plc has filed a Form 13F-NT with the SEC for the quarter ended March 31, 2026, indicating no new holdings are reported in this filing.

Royalty Pharma plc filed a 13F-NT notice for the quarter ended December 31, 2025, indicating its holdings are reported by a sub-manager.

Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini have filed an exit report for their beneficial ownership of Royalty Pharma plc Class A Ordinary Shares, indicating a reduction in their stake to below 5%.

Royalty Pharma plc's CEO and Chairman, Pablo Legorreta, along with Legorreta Investments, LLC, have disclosed a substantial increase in their beneficial ownership of the company's Class A ordinary shares, reaching 19.74% and 8.14% respectively, primarily due to a strategic acquisition transaction.

Key shareholders, GG Strategic and MGG Strategic, have significantly reduced their holdings in Royalty Pharma plc, selling over 4.9 million Class A Ordinary Shares in recent open market transactions.

R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini have filed an amended Schedule 13D for Royalty Pharma plc, revealing a beneficial ownership of 8.3% and significant share sales in the past 60 days.

Capital International Investors reports beneficial ownership of 8.8% of Royalty Pharma PLC's common stock as of March 31, 2026.

Capital International Investors has reported a 6.6% beneficial ownership stake in Royalty Pharma PLC, holding 28,512,128 shares of common stock.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 6.5% beneficial ownership stake in Royalty Pharma PLC's Class A Common Stock as of September 30, 2025.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 2.52% in Royalty Pharma PLC as of September 30, 2025.

General Atlantic and its affiliated entities have disclosed a beneficial ownership of 3.2% in Royalty Pharma plc, holding over 14.2 million Class A ordinary shares.

Capital International Investors has disclosed a 5.5% beneficial ownership stake in Royalty Pharma PLC, holding over 23 million common shares.